- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Scientific reports, 9.2019, Nr. 1, Art. 73, doi:10.1038/s41598-018-36426-9
- Classification
-
Medizin, Gesundheit
- Event
-
Veröffentlichung
- (where)
-
Frankfurt am Main
- (who)
-
Universitätsbibliothek Johann Christian Senckenberg
- (when)
-
2019
- Creator
-
Parra-Rojas, César
Messling, Veronika A. I. von
Hernandez-Vargas, Esteban Abelardo
- URN
-
urn:nbn:de:hebis:30:3-486186
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Parra-Rojas, César
- Messling, Veronika A. I. von
- Hernandez-Vargas, Esteban Abelardo
- Universitätsbibliothek Johann Christian Senckenberg
Time of origin
- 2019
Other Objects (12)
Adjuvanted influenza vaccine dynamics
Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020
Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults
Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
A self-adjuvanted VLPs-based Covid-19 vaccine proven versatile, safe, and highly protective
A modular and self-adjuvanted multivalent vaccine platform based on porcine circovirus virus-like nanoparticles
Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA
Efficacy of an inactivated and adjuvanted “ZULVAC®8 OVIS” vaccine produced using single-use bioreactors
Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults
Adjuvanted influenza vaccine dynamics
Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020
Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults
Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
A self-adjuvanted VLPs-based Covid-19 vaccine proven versatile, safe, and highly protective
A modular and self-adjuvanted multivalent vaccine platform based on porcine circovirus virus-like nanoparticles
Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA
Efficacy of an inactivated and adjuvanted “ZULVAC®8 OVIS” vaccine produced using single-use bioreactors
Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults
Adjuvanted influenza vaccine dynamics
Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020
Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults
Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
A self-adjuvanted VLPs-based Covid-19 vaccine proven versatile, safe, and highly protective
A modular and self-adjuvanted multivalent vaccine platform based on porcine circovirus virus-like nanoparticles
Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA
Efficacy of an inactivated and adjuvanted “ZULVAC®8 OVIS” vaccine produced using single-use bioreactors
Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate